Book chapter
Abacavir pharmacogenomics
Clinical Genomics: Practical Applications in Adult Patient Care
McGraw-Hill Professional
2014
Abstract
Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy for the treatment of the human immunodeficiency virus type 1 (HIV-1) that has been associated with a hypersensitivity reaction in approximately 8% of those starting the drug.
Abacavir hypersensitivity reaction is characterized by greater than or equal to two progressive symptoms typically starting from the second week of therapy (median 9 days) with fever, malaise, nausea, vomiting, diarrhea, and later mild-to-moderate skin rash (present in 70% of patients).
Symptoms of abacavir hypersensitivity resolve rapidly with 24 to 72 hours after drug discontinuation.
A previous clinical history compatible with abacavir hypersensitivity is a contraindication to future rechallenge as severe morbidity and even mortality characterized by hypotension and shock has been described.
Details
- Title
- Abacavir pharmacogenomics
- Authors/Creators
- E.J. Phillips (Author/Creator)S. Mallal (Author/Creator)
- Contributors
- M.F. Murray (Editor)M.W. Babyatsky (Editor)M.A. Giovanni (Editor)F.S. Alkuraya (Editor)D.S. Stewart (Editor)
- Publication Details
- Clinical Genomics: Practical Applications in Adult Patient Care
- Publisher
- McGraw-Hill Professional
- Identifiers
- 991005545187107891
- Copyright
- © 2014 by McGraw-Hill Education
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Book chapter
Metrics
92 Record Views